For research use only. Not for therapeutic Use.
<p style=/line-height:25px/>Vidofludimus(4SC-101; SC12267) is a novel immunosuppressive drug that inhibits DHODH; inhibits IL-17 secretion in vitro independently of effects on lymphocyte proliferation.<br>IC50 value:<br>Target: DHODH inhibitor<br>in vitro: 4SC-101 is a potent inhibitor of human DHODH, inhibits lymphocyte proliferation, and uniquely blocks phytohemagglutinin-stimulated IL-17 production by lymphocytes [2].<br>in vivo: In vivo Vido treatment alone most effectively reduced macroscopic and histological pathology and the numbers of CD3+ T cells. In contrast, similarly reduced nuclear signal transducer and activator of transcription 3 (STAT3) binding and IL-17 levels were observed from animals treated with Vido alone and Vido + Uri. Vido improves TNBS-induced colonic inflammation by a unique dual mode of action [1]. Oral administration of 4SC-101 effectively improved both chronic DSS and acute TNBS colitis in mice. In these colitis models the overall efficacy profile of 4SC-101 was similar to that of dexamethasone [2].</p>
| Catalog Number | I004676 |
| CAS Number | 717824-30-1 |
| Molecular Formula | C20H18FNO4 |
| Purity | ≥95% |
| Target | Dehydrogenase |
| Solubility | DMSO: ≥ 46 mg/mL |
| Storage | Store at -20°C |
| InChI | InChI=1S/C20H18FNO4/c1-26-14-5-2-4-12(10-14)13-8-9-18(17(21)11-13)22-19(23)15-6-3-7-16(15)20(24)25/h2,4-5,8-11H,3,6-7H2,1H3,(H,22,23)(H,24,25) |
| InChIKey | XPRDUGXOWVXZLL-UHFFFAOYSA-N |
| SMILES | COC1=CC(C2=CC(F)=C(NC(C3=C(C(O)=O)CCC3)=O)C=C2)=CC=C1 |
| Reference | </br>1:Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE study. Herrlinger KR, Diculescu M, Fellermann K, Hartmann H, Howaldt S, Nikolov R, Petrov A, Reindl W, Otte JM, Stoynov S, Strauch U, Sturm A, Voiosu R, Ammendola A, Dietrich B, Hentsch B, Stange EF.J Crohns Colitis. 2013 Sep;7(8):636-43. doi: 10.1016/j.crohns.2012.09.016. Epub 2012 Oct 16. PMID: 23078909 </br>2:Vidofludimus inhibits colonic interleukin-17 and improves hapten-induced colitis in rats by a unique dual mode of action. Fitzpatrick LR, Small JS, Doblhofer R, Ammendola A.J Pharmacol Exp Ther. 2012 Sep;342(3):850-60. doi: 10.1124/jpet.112.192203. Epub 2012 Jun 12. PMID: 22691298 Free Article</br>3:New preclinical findings with vidofludimus. [No authors listed]Immunotherapy. 2010 Jul;2(4):439. No abstract available. PMID: 20648986 |
